Junshi Biosciences and Coherus Announce FDA Acceptance of BLA Filing for Toripalimab for Treatment of Nasopharyngeal Carcinoma

NEXT STORY
Statera Biopharma Honors Pancreatic Cancer Awareness Month
PREV STORY
Cabaletta Bio Reports Third Quarter 2021 Financial Results and Provides Business Update
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Rhythm Pharmaceuticals Announces Sale of Priority Review Voucher for $100M

author_avatar
NASDAQ Market News

Oppilan Pharma Announces Positive Phase 1 Data for its Ulcerative Colitis Drug OPL-002 at Digestive Disease Week 2020 Virtual Scientific Program

author_avatar
NASDAQ Market News

Junshi Biosciences and Coherus to Present Positive Progression Free Survival and Overall Survival Results from JUPITER-06, a Phase 3 Clinical Trial Evaluating Toripalimab in Combination with Chemotherapy as First-Line Treatment for Advanced Esophageal Squamous Cell Carcinoma

author_avatar
NASDAQ Market News